Tezacitabine Anhydrous
Who holds supplier records for Tezacitabine Anhydrous? No organisation holds a current US Type II DMF or EU CEP for Tezacitabine Anhydrous in the registers PharmaTek covers. A further 1 organisation has only historical (inactive) DMF filings.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 13 Nov 2026. How we read these records
Cite as: PharmaTek, “Tezacitabine Anhydrous: DMF and CEP holder records”, record as of 13 Nov 2026, pharmatek.co.uk/directory/api/tezacitabine-anhydrous
Reading the evidence
- No current DMF or CEP on record
Only historical filings exist in the covered registers. Any of these organisations may or may not supply today; confirm directly.
Current records (0)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Tezacitabine Anhydrous. Country is the organisation's recorded country, not necessarily the manufacturing site.
Not found in the covered registers (FDA DMF list, EDQM). This is not evidence that no supplier exists.
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (1)
Organisations whose Type II DMFs for Tezacitabine Anhydrous are no longer active. These show a past filing, not current supply.
Show all 1 historical record
- United States · Inactive DMF 11413 · filed Mar 1995
Overview
Tezacitabine Anhydrous is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL2105467).
Chemical identity
- IUPAC name
- 4-amino-1-[(2R,3E,4S,5R)-3-(fluoromethylidene)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
- Canonical SMILES
- C1=CN(C(=O)N=C1N)[C@H]2/C(=C/F)/[C@@H]([C@H](O2)CO)O
- InChIKey
- GFFXZLZWLOBBLO-ASKVSEFXSA-N
- Synonyms
- KW-2331, MDL-101731, Tezacitabina, Tezacitabine anhydrous, Tezacitabine, 2'-Deoxy-2'-(fluoromethylene)cytidine, tezacitabinum, MDL-101,731, RefChem:188974, Anhydrous, FMD-C, FMdC
Record history
PharmaTek records which organisations hold a current DMF or CEP for Tezacitabine Anhydrous every week, starting 23 Oct 2026. Additions and lapses will appear here from the next weekly release.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
What do the historical Tezacitabine Anhydrous records mean?
1 organisation has only inactive Type II DMFs for Tezacitabine Anhydrous. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
How do I qualify a Tezacitabine Anhydrous supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Tezacitabine Anhydrous?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.